Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with... Purpose This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Pacli- taxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). Methods One hundred and seven patients with locally advanced or metastatic gastric adenocarcinoma received intravenous 2 2 infusions of PTX at 135 mg/m and OXA at 85 mg/m on day 1 every 14 days. Results Among 107 patients enrolled, 9 patients could not be evaluated for a response because of the absence of any measur- able lesions. Assessment of the response of 98 patients was made. The overall objective response rate was 42.9% (95% CI 32.9–52.8%), with two complete responses and 40 partial responses. The disease control was 79.6% (95% CI 71.5–87.7%). With 29 months of the median time of follow-up, the median progression-free survival was 5.8 months (95% CI 4.30– 7.30 months) and the median overall survival was 11.5 months (95% CI 9.08–13.9 months). The 1-year survival rate was 48.0%. The most common grades 3 and 4 toxicities included neutropenia (32.7%), leucopenia (17.8%), fatigue (5.61%), and anemia (4.67%). Peripheral neuropathy occurred in 23.4% patients and grade 2 or higher peripheral neuropathy occurred in 12.1% of the patients. Conclusions Combination chemotherapy with PTX and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Download PDF
9 pages

Loading next page...
 
/lp/springer_journal/combination-chemotherapy-with-paclitaxel-and-oxaliplatin-as-first-line-UFJLPySLU0

References (29)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-018-3576-x
Publisher site
See Article on Publisher Site

Abstract

Purpose This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Pacli- taxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). Methods One hundred and seven patients with locally advanced or metastatic gastric adenocarcinoma received intravenous 2 2 infusions of PTX at 135 mg/m and OXA at 85 mg/m on day 1 every 14 days. Results Among 107 patients enrolled, 9 patients could not be evaluated for a response because of the absence of any measur- able lesions. Assessment of the response of 98 patients was made. The overall objective response rate was 42.9% (95% CI 32.9–52.8%), with two complete responses and 40 partial responses. The disease control was 79.6% (95% CI 71.5–87.7%). With 29 months of the median time of follow-up, the median progression-free survival was 5.8 months (95% CI 4.30– 7.30 months) and the median overall survival was 11.5 months (95% CI 9.08–13.9 months). The 1-year survival rate was 48.0%. The most common grades 3 and 4 toxicities included neutropenia (32.7%), leucopenia (17.8%), fatigue (5.61%), and anemia (4.67%). Peripheral neuropathy occurred in 23.4% patients and grade 2 or higher peripheral neuropathy occurred in 12.1% of the patients. Conclusions Combination chemotherapy with PTX and

Journal

Cancer Chemotherapy and Pharmacology – Springer Journals

Published: Apr 4, 2018

There are no references for this article.